LifeMD reported second quarter 2026 revenue of $47.3 million, within its guidance range of $47 million to $50 million, and an adjusted EBITDA loss of approximately $3.5 million, a sequential improvement of about 21%. The company said approximately 95% of new weight management patients now start on branded GLP-1 therapies, marking the effective end of its transition away from compounded GLP-1 medications. Gross margin expanded roughly 280 basis points year-over-year to about 89%, driven by lower shipping and fulfillment costs and scaling of its in-house pharmacy. Weight Management Program subscribers grew to approximately 108,000, and total active subscribers rose 20% year-over-year to roughly 356,000. LifeMD also launched an exclusive telehealth co-marketing collaboration with Halozyme’s subsidiary Antares Pharma for XYOSTED, the only FDA-approved once-weekly subcutaneous testosterone auto-injector. The company exited the quarter with $25.1 million in cash, no debt, and $30 million of additional liquidity under its revolving credit facility. It expects a return to positive adjusted EBITDA in the second half of 2026 and a fourth-quarter exit revenue run rate of approximately $250 million with about $22 million of annualized adjusted EBITDA. Full-year 2026 guidance was revised to revenue of $205.5 million to $212.5 million and adjusted EBITDA of negative $6.0 million to breakeven, including $2 million to $3 million of net launch costs for XYOSTED.
LifeMD IncRevenue within guidance, narrowed full-year guidance, improved EBITDA, and strong subscriber growth.
